Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. - sprookjes - yvandenbroek - TriplyDB

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity.

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity.

http://www.wikidata.org/entity/Q33989536

about

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.Emerging Techniques in Brain Tumor Imaging: What Radiologists Need to Know Nuclear Overhauser Enhancement imaging of glioblastoma at 7 Tesla: region specific correlation with apparent diffusion coefficient and histology DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study Parameterizing the Logistic Model of Tumor Growth by DW-MRI and DCE-MRI Data to Predict Treatment Response and Changes in Breast Cancer Cellularity during Neoadjuvant Chemotherapy.Diffusion-weighted MRI as a biomarker for treatment response in glioma Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics.Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Relationship between Apparent Diffusion Coefficients and MR Spectroscopy Findings in High-Grade Gliomas.Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria)Advances in MRI assessment of gliomas and response to anti-VEGF therapy.Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas.Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab sfDM: Open-Source Software for Temporal Analysis and Visualization of Brain Tumor Diffusion MR Using Serial Functional Diffusion Mapping.Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.Bony metastases: assessing response to therapy with whole-body diffusion MRI.Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma.Multi-modal imaging of tumor cellularity and Tryptophan metabolism in human Gliomas.Automatic Analysis of Cellularity in Glioblastoma and Correlation with ADC Using Trajectory Analysis and Automatic Nuclei Counting Early Detection of Malignant Transformation in Resected WHO II Low-Grade Glioma Using Diffusion Tensor-Derived Quantitative Measures.Survival analysis for apparent diffusion coefficient measures in children with embryonal brain tumours.Development of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment.Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma.

P2860

Q26801351-6B286960-7ED9-4A36-ADD0-725A0328A976 Q27342179-0C615A38-DF89-41DA-84E7-CEE2082E3483 Q28068259-6B3316F8-DD3C-410A-BF50-45CCEC567008 Q28544667-7CB40CFD-8ABC-425A-A1F5-B613241A55B3 Q28730443-2044C960-91B0-49F8-862E-53D5734914B3 Q30413713-4BE32C61-5DBE-49BB-9F04-7ADBD2BD97CF Q30639288-0EEB9F77-963B-47B0-96B3-90D347F18C41 Q30660991-B76120EF-FF5D-414A-B50A-B1DA1D6A37AA Q30764736-7E727DB4-CBCF-47C5-9256-DE226988E175 Q30847284-AF60D44E-98BB-480B-B6A9-FE72BC3EF00C Q30870628-19E81930-7109-4F85-9A4B-E0F8A10E0372 Q30891381-CF7F18F3-7052-4C09-8798-0F619241BAFA Q30907831-F620D2DB-49D6-42BE-B5A3-49136406C6B4 Q31077412-3542A928-B867-4F5A-A23A-1D73DC945E42 Q33616589-D0FE9FEC-BBD2-4C2A-8675-FE90FC970341 Q33649467-9EF52D13-796F-42E7-A498-A719EDDC5F55 Q33793253-DCD2BE05-8453-4404-87C4-72E09FB029A4 Q33905155-EDB8362B-FEAF-42F5-A81C-B9CB5939437F Q34331320-57914A3B-C7E0-4204-A5B3-25CAEC1132DE Q34511741-9DDBA0C1-E633-4986-A105-CB8A0C780100 Q34553361-D741CD10-2D19-4ABD-9781-7BC81372E0A1 Q34731176-39D25959-496C-45B6-AD6F-3C9A745C0306 Q35018356-C8DE0F9A-C7C3-42A8-95B9-20BE8E879256 Q35028897-5F22B724-0C28-460A-9513-5ED9F8EB316A Q35042226-DB2AC3DD-A86B-46CF-94FB-8A8163924EA4 Q35115962-62F19C2D-E219-49CA-B85C-80408D2C7475 Q35224703-BC0CE9C4-498E-40C2-8683-11781FA5D616 Q35225259-3CADC479-9BA8-43BC-99A3-E8AF76D90623 Q35598954-A01C3EA7-DDE2-44E3-BD29-E86511999B4F Q35697593-F1A6CF91-03B9-4B5D-BF55-431B93945218 Q35760662-1AF84BB7-DC70-416D-9316-B4D3E56A7850 Q35771783-45A844E6-15C2-48B1-B81F-088F1205A5FD Q35783021-A9FE7267-F148-4A6B-B99C-62224AC74AAE Q35849699-1FB09977-154E-499B-8931-76845BFCF995 Q35923158-4CB51510-2FA1-42DE-AE2E-0B26E5DC5F02 Q36088683-5AA42F41-66A7-479B-86C1-CF3DA89C64F3 Q36164058-D234E957-2790-44A1-81E5-CC24ADFC30D1 Q36261344-B7EDFDEF-FB2A-4E8F-B5C9-1B60A6947EB7 Q36275542-7B46F659-C56A-4AD4-8B9A-BC1C7993C13B Q36279602-5ABA7B91-C45D-4297-9918-FB4C77D3EEDE

P2860

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity.

http://www.wikidata.org/entity/Q33989536

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Validation of functional diffu ...... for human glioma cellularity.

@ast

Validation of functional diffu ...... for human glioma cellularity.

@en

type

label

Validation of functional diffu ...... for human glioma cellularity.

@ast

Validation of functional diffu ...... for human glioma cellularity.

@en

prefLabel

Validation of functional diffu ...... for human glioma cellularity.

@ast

Validation of functional diffu ...... for human glioma cellularity.

@en

P1433

Q33989536-018B3484-B75F-41F4-AFDD-8A88D1E977E5

P1476

Q33989536-422A11B7-A4FF-4C60-9AA6-FA826A6FE536

P2093

Q33989536-16E5F511-091F-4FD6-AAF8-91D8322529C3

Q33989536-4B5D9763-99E4-4806-97EB-6D4B65EF72F6

Q33989536-56B7AB2F-B613-434B-8C15-D31A2E02B1F3

Q33989536-5A07F004-62D2-45ED-81DB-876DBF47C0E5

Q33989536-90CB2AD3-B754-429B-AFA4-072E0B29CB7B

Q33989536-9A825DD1-B05C-4F03-AE59-744504ABC3F4

Q33989536-BDC93434-2DFC-47AA-8A6E-D2C84D7FF9B7

Q33989536-F35DCBD0-2C6D-463A-BAB3-62C5C9F93985

P2860

Q33989536-01A62AEC-B890-4234-A94E-E00572188628

Q33989536-1ABDF5B0-DEB6-431A-AE57-1CE67E3D9A07

Q33989536-35A4A603-959B-450D-BDEA-644ACCFC6CB4

Q33989536-37F85CCD-239F-44C9-B812-3D4F0073AB8E

Q33989536-42150B47-D8D3-4ABA-B02F-174D4151890E

Q33989536-49DD553F-47F2-46CF-B529-7F5797904BC6

Q33989536-51091C08-C09E-4CD4-B390-1356C55DA410

Q33989536-53F75F6D-608A-43BF-AD72-D03E9DE751D3

Q33989536-57912BB6-A273-4745-ABEF-58EA17B199B7

Q33989536-71BAA204-FAC0-44FF-AD4C-A145D311B442

P304

Q33989536-52920693-5B25-492D-9DDE-826127A82F32

P31

Q33989536-9E941323-07D0-486B-A599-4C98EE45BCDE

P356

Q33989536-F846D7C6-9CED-4710-AE0A-CF6CBEA8A07E

P433

Q33989536-46C6CA02-261A-4948-8411-FCC77E42538E

P478

Q33989536-2ABC5378-1A9F-4848-B9B1-01740F568433

P577

Q33989536-7C238C05-30A1-40B0-A337-A098A47B1FC5

P5875

Q33989536-A3639A7D-91B2-44FF-8A8D-894C4557DBF6

P698

Q33989536-39F10BB7-7A51-4EE3-A459-9982AAEEBCE4

P921

Q33989536-FFBE72A3-A4F9-4058-9B7A-5EC586A09C42

P932

Q33989536-090558FD-884D-4F53-9C1A-FC6734D19925

P356

P1433

Journal of Magnetic Resonance Imaging

P1476

Validation of functional diffu ...... for human glioma cellularity.

@en

P2093

Benjamin M Ellingson

http://www.w3.org/2001/XMLSchema#string

Carolyn Quinsey

http://www.w3.org/2001/XMLSchema#string

Devyani P Bedekar

http://www.w3.org/2001/XMLSchema#string

Jennifer M Connelly

http://www.w3.org/2001/XMLSchema#string

Kathleen M Schmainda

http://www.w3.org/2001/XMLSchema#string

Mark G Malkin

http://www.w3.org/2001/XMLSchema#string

Pete S LaViolette

http://www.w3.org/2001/XMLSchema#string

Scott D Rand

http://www.w3.org/2001/XMLSchema#string

P2860

Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.

Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging.

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.

Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.

Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion.

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity.

P304

538-548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMRI.22068

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41579849

http://www.w3.org/2001/XMLSchema#string

P698

20187195

http://www.w3.org/2001/XMLSchema#string

P921

P932

2903058

http://www.w3.org/2001/XMLSchema#string